Gewinnerbranchen der Jahre 2006 bis 2040 - Älteste Beiträge zuerst (Seite 8707)
eröffnet am 10.12.06 16:57:17 von
neuester Beitrag 16.02.24 09:33:08 von
neuester Beitrag 16.02.24 09:33:08 von
Beiträge: 94.068
ID: 1.099.361
ID: 1.099.361
Aufrufe heute: 11
Gesamt: 3.535.853
Gesamt: 3.535.853
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 6412 | |
| vor 37 Minuten | 4699 | |
| vor 12 Minuten | 4509 | |
| heute 18:00 | 3177 | |
| vor 25 Minuten | 2746 | |
| vor 47 Minuten | 2692 | |
| heute 20:23 | 2036 | |
| vor 1 Stunde | 1670 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.716,00 | -0,19 | 203 | |||
| 2. | 2. | 137,91 | -2,27 | 92 | |||
| 3. | 7. | 6,6460 | -1,23 | 70 | |||
| 4. | 5. | 0,1835 | -2,65 | 56 | |||
| 5. | 8. | 3,7675 | +0,74 | 55 | |||
| 6. | Neu! | 669,50 | -22,89 | 45 | |||
| 7. | 17. | 7,2825 | -0,24 | 45 | |||
| 8. | 4. | 2.390,67 | +0,47 | 40 |
Feedback
zu GLPG. sehr gute Nachricht.
https://www.marketscreener.com/GALAPAGOS-6464/news/Orphan-Dr…
Orphan Drug Designation for GLPG1690 in systemic sclerosis
01/29/2020 | 02:00am EST
Mechelen, Belgium; 29 January 2020, 8.00 CET – Galapagos NV (Euronext & NASDAQ: GLPG) announces today that the US Food & Drug Administration (FDA) and the European Commission (EC) have granted investigational autotaxin inhibitor GLPG1690 ‘orphan drug designation’ for the treatment of systemic sclerosis (SSc).
In order to stimulate the pharmaceutical industry to develop and market medicines for diseases affecting a small number of patients, the EC and the FDA offer a range of incentives to encourage the development of these ‘orphan’ medicines for rare diseases in the European Union and the United States. These incentives include amongst others 7 to 10 years of market exclusivity once the medicine is on the market, regulatory fee reductions and fee waivers and access to the centralized procedure for marketing authorization in Europe.1,2
“We are happy to see that the EC and FDA recognize GLPG1690 as a potential new treatment for SSc patients. With the NOVESA Phase 2 trial in SSc fully recruited, we expect to see topline data in the second half of the year,” said Dr. Walid-Abi-Saab, CMO of Galapagos.
About SSc
Diffuse cutaneous systemic sclerosis (SSc) is an autoimmune disease involving multiorgan fibrosis, which has one of the highest mortality rates among rheumatic diseases.3 One of the most visible manifestions is hardening of the skin. In diffuse cutaneous SSc, skin thickening affects several body areas, and patients have a higher risk of developing fibrosis of various internal organs, such as the lung. Currently, there are no approved drugs for this disease. SSc affects approximately 90,000 patients in the US and Europe, with a predominance of female patients (75%).
https://www.marketscreener.com/GALAPAGOS-6464/news/Orphan-Dr…
Orphan Drug Designation for GLPG1690 in systemic sclerosis
01/29/2020 | 02:00am EST
Mechelen, Belgium; 29 January 2020, 8.00 CET – Galapagos NV (Euronext & NASDAQ: GLPG) announces today that the US Food & Drug Administration (FDA) and the European Commission (EC) have granted investigational autotaxin inhibitor GLPG1690 ‘orphan drug designation’ for the treatment of systemic sclerosis (SSc).
In order to stimulate the pharmaceutical industry to develop and market medicines for diseases affecting a small number of patients, the EC and the FDA offer a range of incentives to encourage the development of these ‘orphan’ medicines for rare diseases in the European Union and the United States. These incentives include amongst others 7 to 10 years of market exclusivity once the medicine is on the market, regulatory fee reductions and fee waivers and access to the centralized procedure for marketing authorization in Europe.1,2
“We are happy to see that the EC and FDA recognize GLPG1690 as a potential new treatment for SSc patients. With the NOVESA Phase 2 trial in SSc fully recruited, we expect to see topline data in the second half of the year,” said Dr. Walid-Abi-Saab, CMO of Galapagos.
About SSc
Diffuse cutaneous systemic sclerosis (SSc) is an autoimmune disease involving multiorgan fibrosis, which has one of the highest mortality rates among rheumatic diseases.3 One of the most visible manifestions is hardening of the skin. In diffuse cutaneous SSc, skin thickening affects several body areas, and patients have a higher risk of developing fibrosis of various internal organs, such as the lung. Currently, there are no approved drugs for this disease. SSc affects approximately 90,000 patients in the US and Europe, with a predominance of female patients (75%).
Neuvorstellung Polight ASA.
https://www.polight.com/home/default.aspx
"After more than a decade of research and development aimed at replicating the lens of the human eye, poLight is now ready to introduce to the market a technology that captures astonishing images with instant focus."
Polight ASA, formerly known as Polight AS, is a Norway-based manufacturer of photographic lens for mobile devices. The Company uses technology TLens that replicates the lens of the human eye and enables production of wafer scale, active optical components based on shapeable polymers. The Company’s products are TLens Silver Premium and TLens Platinum lens. In addition, the Company offers its own ASIC driver (Project Development Assistance 50) used to supply variable voltage to all TLens products to change focusing. The Company operates in Norway, Finland, France, Hong Kong and China.
Number of employees : 34 people.
https://s22.q4cdn.com/177975322/files/doc_financials/2019/q3…
Unternehmen kommt in die breite Markteinführungsphase. Sehr viele Anwendungen möglich. ST Microelectronics stellt die wafer her. Assembly in China. Beobachten.
https://www.polight.com/home/default.aspx
"After more than a decade of research and development aimed at replicating the lens of the human eye, poLight is now ready to introduce to the market a technology that captures astonishing images with instant focus."
Polight ASA, formerly known as Polight AS, is a Norway-based manufacturer of photographic lens for mobile devices. The Company uses technology TLens that replicates the lens of the human eye and enables production of wafer scale, active optical components based on shapeable polymers. The Company’s products are TLens Silver Premium and TLens Platinum lens. In addition, the Company offers its own ASIC driver (Project Development Assistance 50) used to supply variable voltage to all TLens products to change focusing. The Company operates in Norway, Finland, France, Hong Kong and China.
Number of employees : 34 people.
https://s22.q4cdn.com/177975322/files/doc_financials/2019/q3…
Unternehmen kommt in die breite Markteinführungsphase. Sehr viele Anwendungen möglich. ST Microelectronics stellt die wafer her. Assembly in China. Beobachten.
Antwort auf Beitrag Nr.: 62.519.723 von clearasil am 29.01.20 13:41:39About us
poLight ASA is a Norwegian company, headquartered in Horten, which is about to introduce a unique photographic lens to the market for mobile devices. Replicating the lens of the human eye, poLight®’s TLens® enables new user experiences, and eases implementation of autofocus functions for various applications.
The patented, proprietary technology, which has been developed over more than ten years, enables production of wafer scale (MEMS), active optical components based on shapeable polymers. poLight’s TLens offers the camera module market considerable benefits, such as extremely fast focus, compact xy-dimension, no electromagnetic interference, no impact by gravity, low power consumption, and constant field of view. These features accommodate easy installation of single and multi-camera implementations, while achieving high optical quality.
poLight has offices in Norway, Finland, China and France, and is represented in Korea, Taiwan and Japan. The company was founded in 2005, and has since built state-of-the-art expertise in optics, polymers, MEMS technology, and image applications and processing. The poLight team comprises world-class researchers and developers, all aiming to develop the world’s leading imaging technologies.
poLight ASA is a Norwegian company, headquartered in Horten, which is about to introduce a unique photographic lens to the market for mobile devices. Replicating the lens of the human eye, poLight®’s TLens® enables new user experiences, and eases implementation of autofocus functions for various applications.
The patented, proprietary technology, which has been developed over more than ten years, enables production of wafer scale (MEMS), active optical components based on shapeable polymers. poLight’s TLens offers the camera module market considerable benefits, such as extremely fast focus, compact xy-dimension, no electromagnetic interference, no impact by gravity, low power consumption, and constant field of view. These features accommodate easy installation of single and multi-camera implementations, while achieving high optical quality.
poLight has offices in Norway, Finland, China and France, and is represented in Korea, Taiwan and Japan. The company was founded in 2005, and has since built state-of-the-art expertise in optics, polymers, MEMS technology, and image applications and processing. The poLight team comprises world-class researchers and developers, all aiming to develop the world’s leading imaging technologies.
Antwort auf Beitrag Nr.: 62.517.302 von clearasil am 29.01.20 10:03:35
Hallo Clea,
Erst noch mal vielen Dank für die Tips.
Ich habe sie beherzigt. :-)
Zu bee vectoring .
Das hört sich alles gut und schön an.
Bienen sind toll, jeder will helfen und dann noch gutes tun und Geld damit verdienen.
Doch leider ist das eine Canda Firma , dort sind die Standarts extrem niedrig. Die Berichterstattung für ein Unternehmen mit 59,000 $ Umsatz, ging erst richtig los nach dem Anstieg. Laut Geschäftsbericht müsste bald das Geld alle sein und hier bei WO ein Thread mit den üblichen aggressiven pushern die ich von den üblichen Kanada Klitschen kennne ...
VG codiman
Zu schön um Wahr zu sein.
Zitat von clearasil: Bienengesummse.
Bee Vectoring Technologies Closes Grower Deals in Three New Markets
Wed January 29, 2020 1:00 AM|Newsfile|About: BEVVF
Newsfile Corp
Mississauga, Ontario and Sacramento, California--(Newsfile Corp. - January 29, 2020) - Bee Vectoring Technologies International Inc. (BEVVF) (TSXV: BEE) (OTCQB: BEVVF) (the "Company" or "BVT") today announced that it has closed five new deals with blueberry growers in Florida, North Carolina and South Carolina to use BVT's proprietary bee delivery system VECTORITE™ with CR-7, on portions of their crops in the upcoming growing season.
In the five months since US Environmental Protection Agency approval, BVT has secured committed business with growers who collectively represent about 10% of blueberries grown in the Southeastern US and exceeded its sales target for that market. The Company's original target for blueberry growers in the US Southeast was 10 growers and 500 acres; however with these agreements in place BVT has surpassed this goal and will now cover 700 acres with 15 growers across the region.
https://seekingalpha.com/pr/17762181-bee-vectoring-technolog…
Hallo Clea,
Erst noch mal vielen Dank für die Tips.
Ich habe sie beherzigt. :-)
Zu bee vectoring .
Das hört sich alles gut und schön an.
Bienen sind toll, jeder will helfen und dann noch gutes tun und Geld damit verdienen.
Doch leider ist das eine Canda Firma , dort sind die Standarts extrem niedrig. Die Berichterstattung für ein Unternehmen mit 59,000 $ Umsatz, ging erst richtig los nach dem Anstieg. Laut Geschäftsbericht müsste bald das Geld alle sein und hier bei WO ein Thread mit den üblichen aggressiven pushern die ich von den üblichen Kanada Klitschen kennne ...
VG codiman
Antwort auf Beitrag Nr.: 62.520.206 von codiman am 29.01.20 14:20:14Doch leider ist das eine Canda Firma , dort sind die Standarts extrem niedrig. Die Berichterstattung für ein Unternehmen mit 59,000 $ Umsatz, ging erst richtig los nach dem Anstieg. Laut Geschäftsbericht müsste bald das Geld alle sein und hier bei WO ein Thread mit den üblichen aggressiven pushern die ich von den üblichen Kanada Klitschen kennne ...
das ist alles richtig.
mal schauen.
das ist alles richtig.
mal schauen.
Trading Spotlight
@clearasil
Unser edler Freund hatte letztes Jahr mit seinem Hedge Fonds das erfolgreichste Jahr seit 2000 von +53,7%
https://www.institutionalinvestor.com/article/b1jx6kyv36vdb0…
Unser edler Freund hatte letztes Jahr mit seinem Hedge Fonds das erfolgreichste Jahr seit 2000 von +53,7%
https://www.institutionalinvestor.com/article/b1jx6kyv36vdb0…
Antwort auf Beitrag Nr.: 62.520.791 von flying.kangaroo am 29.01.20 15:10:20er is schon ne coole sau. 
🦌📢
🦌📢
Noch ein 
recht unbekannter Genomdiagnostiker: www.veracyte.com
https://investor.veracyte.com/static-files/2322d1d4-9106-496…
https://financials.morningstar.com/ratios/r.html?t=VCYT
www.finanzen.net/schaetzungen/veracyte
Kursverlauf seit Börsengang Herbst 2013:
recht unbekannter Genomdiagnostiker: www.veracyte.com
https://investor.veracyte.com/static-files/2322d1d4-9106-496…
https://financials.morningstar.com/ratios/r.html?t=VCYT
www.finanzen.net/schaetzungen/veracyte
Kursverlauf seit Börsengang Herbst 2013:
zu ALBO.
https://www.marketscreener.com/ALBIREO-PHARMA-INC-31816183/n…
ist ja einer meiner faves für 2020 und beyond. war gestern jede menge los. Es wird erwartbarerweise eine KE geben, dürfte kurzfristig druck auf den kurs bringen. Interessierte können das als chance begreifen.
https://seekingalpha.com/pr/17763581-albireo-prices-40-milli…
folgendes wird fundamental passieren:
“We expect our Phase 3 trial in PFIC will be fully randomized in the coming days, and we expect to report topline data in mid-2020. Today, I am particularly excited to announce that the FDA has cleared our IND, and we expect to initiate a precedent-setting pivotal trial in biliary atresia in the first half of 2020. Following FDA input later this quarter, we plan to initiate a third odevixibat pivotal trial, in Alagille syndrome, later this year. We are a growing, energized and well-prepared organization, and look forward to 2020 being a transformational year for Albireo.”
https://www.marketscreener.com/ALBIREO-PHARMA-INC-31816183/n…
ist ja einer meiner faves für 2020 und beyond. war gestern jede menge los. Es wird erwartbarerweise eine KE geben, dürfte kurzfristig druck auf den kurs bringen. Interessierte können das als chance begreifen.
https://seekingalpha.com/pr/17763581-albireo-prices-40-milli…
folgendes wird fundamental passieren:
“We expect our Phase 3 trial in PFIC will be fully randomized in the coming days, and we expect to report topline data in mid-2020. Today, I am particularly excited to announce that the FDA has cleared our IND, and we expect to initiate a precedent-setting pivotal trial in biliary atresia in the first half of 2020. Following FDA input later this quarter, we plan to initiate a third odevixibat pivotal trial, in Alagille syndrome, later this year. We are a growing, energized and well-prepared organization, and look forward to 2020 being a transformational year for Albireo.”
Antwort auf Beitrag Nr.: 62.530.088 von clearasil am 30.01.20 11:07:28Dankeschön.
ALBO könnte nun doch noch mein Kauflimit von $20,xx erreichen
Bin auf die KE-Beteiligten gespannt - dürfte neben Cbear Advisors die üblichen Größen sein
ALBO könnte nun doch noch mein Kauflimit von $20,xx erreichen
Bin auf die KE-Beteiligten gespannt - dürfte neben Cbear Advisors die üblichen Größen sein
DurchsuchenBeitrag zu dieser Diskussion schreiben
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 203 | ||
| 92 | ||
| 70 | ||
| 56 | ||
| 55 | ||
| 45 | ||
| 45 | ||
| 40 | ||
| 33 | ||
| 27 |
| Wertpapier | Beiträge | |
|---|---|---|
| 22 | ||
| 20 | ||
| 20 | ||
| 19 | ||
| 18 | ||
| 18 | ||
| 18 | ||
| 17 | ||
| 16 | ||
| 15 |
